You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 117 No. 1, January 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (52)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Cardiovascular System
 •Thrombolysis
 •Alert me on articles by topic

Heritable Thrombophilia and Hypofibrinolysis

Possible Causes of Retinal Vein Occlusion

Charles J. Glueck, MD; Howard Bell, MD; Lou Vadlamani, MD; Arun Gupta, PhD; Robert N. Fontaine, PhD; Ping Wang, PhD; Davis Stroop, MS; Ralph Gruppo, MD

Arch Ophthalmol. 1999;117:43-49.

Objective  To determine whether heritable thrombophilia and hypofibrinolysis were risk factors for retinal vein occlusion.

Design  Measures of thrombophilia (increased likelihood of thrombus formation) included anticardiolipin antibodies (IgG and IgM), the lupus anticoagulant (including dilute Russell viper venom clotting time), antigenic proteins C and S, and homocysteine. Polymerase chain reaction assays were performed for 3 thrombophilic gene mutations (factor V Leiden, methylenetetrahydrofolate reductase, and prothrombin gene). Measures of hypofibrinolysis (reduced ability to lyse thrombi) included lipoprotein Lp(a), plasminogen activator inhibitor activity, and polymerase chain reaction analysis of the hypofibrinolytic 4G/5G polymorphism of the PAI1 gene. These coagulation measures were performed in 17 patients with retinal vein occlusions with comparison with serologic coagulation measures and polymerase chain reaction assays in 40 and 234 healthy normal volunteers as controls, respectively.

Results  Of 14 patients with retinal vein occlusion with measures of dilute Russell viper venom clotting time, a thrombophilic antiphospholipid antibody, 6 (43%) had abnormal results (>38.8 seconds) compared with 1 (3%) of 30 controls (P=.002). Of 17 patients with vein occlusion, 3 (18%) were heterozygous for the thrombophilic factor V Leiden G1691A mutation compared with 7 (3%) of 233 controls (P=.02). Of 17 patients with vein occlusion, 2 (12%) had normal alleles (5G/5G) for the plasminogen activator inhibitor gene promoter; the other 15 (88%) were heterozygous or homozygous for the 4G polymorphism, which is associated with hypofibrinolysis. Of 234 controls, 85 (36.3%) had the 5G/5G allele; 149 (63.7%) were heterozygous or homozygous for the 4G polymorphism (P= .03). Patients with vein occlusion were more likely to have high levels of the major determinant of hypofibrinolysis, plasminogen activator inhibitor activity. These levels were high (>22 U/L) in 6 (38%) of 16 patients with vein occlusion compared with 1 (2%) of 40 controls ({chi}2=12.8; P=.001). Patients with vein occlusion were more likely (8/16 [50%]) to have high levels of hypofibrinolytic Lp(a) (>35 mg/dL) than controls (5/40 [13%]; {chi}2=9; P=.003). The median Lp(a) level in patients with vein occlusion who had the 4G/4G genotype was 62 mg/dL compared with 5.3 mg/dL in controls with the 4G/4G genotype (P=.05).

Conclusion  Thrombophilia and hypofibrinolysis are possible causes of retinal vein occlusion.


From the Cholesterol Center (Drs Glueck, Vadlamani, and Wang) and the Ophthalmology Division (Dr Bell), Jewish Hospital; the Molecular Diagnostics and Research Center (Drs Gupta and Fontaine) and Hematology/Oncology Division (Mr Stroop and Dr Gruppo), Children's Hospital, Cincinnati, Ohio.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ocular Vascular Thrombotic Events: Central Retinal Vein and Central Retinal Artery Occlusions
Glueck et al.
CLIN APPL THROMB HEMOST 2008;14:286-294.
ABSTRACT  

Retinal Vein Occlusion, Homocysteine, and Methylene Tetrahydrofolate Reductase Genotype
McGimpsey et al.
IOVS 2005;46:4712-4716.
ABSTRACT | FULL TEXT  

Associations of Thrombophilia, Hypofibrinolysis, and Retinal Vein Occlusion
Glueck et al.
CLIN APPL THROMB HEMOST 2005;11:375-389.
ABSTRACT  

Idiopathic Intracranial Hypertension: Associations with Thrombophilia and Hypofibrinolysis in Men
Glueck et al.
CLIN APPL THROMB HEMOST 2005;11:441-448.
ABSTRACT  

Amaurosis Fugax: Associations with Heritable Thrombophilia
Glueck et al.
CLIN APPL THROMB HEMOST 2005;11:235-241.
ABSTRACT  

Ramifications of Four Concurrent Thrombophilic Mutations and One Hypofibrinolytic Mutation
Glueck et al.
CLIN APPL THROMB HEMOST 2004;10:365-371.
ABSTRACT  

Clinical Course of Younger Patients With Central Retinal Vein Occlusion
Recchia et al.
Arch Ophthalmol 2004;122:317-321.
ABSTRACT | FULL TEXT  

Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion
Hvarfner et al.
Br. J. Ophthalmol. 2003;87:305-306.
ABSTRACT | FULL TEXT  

Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease
CHAK et al.
Br. J. Ophthalmol. 2001;85:883-886.
FULL TEXT  

Genetic Hypofibrinolysis in Complicated Pregnancies
GLUECK et al.
Obstet Gynecol 2001;97:44-48.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.